Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Jazz Pharmaceuticals News

Aktie
WKN:  A1JS1K ISIN:  IE00B4Q5ZN47 US-Symbol:  JAZZ Branche:  Biotechnologie Land:  Irland
165,94 €
-2,16 €
-1,28%
12:13:07 Uhr
Depot/Watchlist
Marktkapitalisierung *
8,78 Mrd. €
Streubesitz
-
KGV
-
Nachhaltigkeits-Score
37 %
Index-Zuordnung
-
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,29: JZ07T3
Werbung

Jazz Pharmaceuticals News

10.04.26 wallstreetONLINE Redaktion
Bristol Myers, Merck oder Jazz: Die besten Pharma-Aktien für die Quartalssaison
US-​Pharmaaktien haben den Markt zuletzt klar geschlagen – doch genau das macht sie anfällig. Bank of America nennt 4 Favoriten für die Quartalssaison und erklärt, warum Zölle ...
09.04.26 - PR Newswire
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American ...
01.04.26 - PR Newswire
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference PR Newswire
01.04.26 - PR Newswire
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference PR Newswire
24.03.26 - PR Newswire
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-​Based Sodium Reduction and Cardiovascular Health Education PR Newswire
18.03.26 - PR Newswire
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-​Clinical Data Advancing Oncology Research at AACR 2026 PR Newswire
24.02.26 - PR Newswire
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance PR Newswire
24.02.26 - PR Newswire
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance PR Newswire
17.02.26 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire
17.02.26 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire
10.02.26 - PR Newswire
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 PR Newswire
10.02.26 - PR Newswire
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 PR Newswire
08.01.26 - PR Newswire
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer PR Newswire
06.01.26 - PR Newswire
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
Ziihera® (zanidatamab-​hrii) Combinations Achieve Unprecedented Results in First-​Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall ...
17.12.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Jazz Pharmaceuticals to Participate in Upcoming Investor Events PR Newswire
17.12.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Jazz Pharmaceuticals to Participate in Upcoming Investor Events PR Newswire
05.12.25 - PR Newswire
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Jazz Pharmaceuticals to Present Extensive New Data and Real-​World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-​Resistant Epilepsies at the American ...
02.12.25 - PR Newswire
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-​hrii) Combinations in First-​Line HER2-Positive Locally Advanced or Metastatic ...
18.11.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference PR Newswire
18.11.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
16.04.26 -0,42%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »